These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1907839)

  • 21. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Rogers JD; Zhao J; Liu L; Amin RD; Gagliano KD; Porras AG; Blum RA; Wilson MF; Stepanavage M; Vega JM
    Clin Pharmacol Ther; 1999 Oct; 66(4):358-66. PubMed ID: 10546919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
    Olbricht C; Wanner C; Eisenhauer T; Kliem V; Doll R; Boddaert M; O'Grady P; Krekler M; Mangold B; Christians U
    Clin Pharmacol Ther; 1997 Sep; 62(3):311-21. PubMed ID: 9333107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias.
    Aronson JK; Ng LL
    Q J Med; 1990 Feb; 74(274):111-5. PubMed ID: 2111916
    [No Abstract]   [Full Text] [Related]  

  • 26. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
    Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of itraconazole on the pharmacokinetics of atorvastatin.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of rat brain prostaglandin D synthase by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Islam F; Watanabe Y; Hayaishi O
    Biochem Int; 1990 Nov; 22(4):601-5. PubMed ID: 2127671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
    Dieterle W; Corynen S; Vaidyanathan S; Mann J
    Int J Clin Pharmacol Ther; 2005 Nov; 43(11):527-35. PubMed ID: 16300168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
    Chen C; Lin J; Smolarek T; Tremaine L
    Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic interaction between isradipine and lovastatin in normal, female and male volunteers.
    Zhou LX; Finley DK; Hassell AE; Holtzman JL
    J Pharmacol Exp Ther; 1995 Apr; 273(1):121-7. PubMed ID: 7714757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of clinical trials comparing HMG-CoA reductase inhibitors.
    Illingworth DR; Tobert JA
    Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
    Miettinen TA
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S19-21. PubMed ID: 1904356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):99-110. PubMed ID: 9221829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.